SCD1 Inhibition Causes Cancer Cell Death by Depleting Mono-Unsaturated Fatty Acids by Mason, Paul et al.
SCD1 Inhibition Causes Cancer Cell Death by Depleting
Mono-Unsaturated Fatty Acids
Paul Mason*, Beirong Liang, Lingyun Li, Trisha Fremgen, Erin Murphy, Angela Quinn, Stephen L. Madden,
Hans-Peter Biemann, Bing Wang, Aharon Cohen, Svetlana Komarnitsky, Kate Jancsics, Brad Hirth,
Christopher G. F. Cooper, Edward Lee, Sean Wilson, Roy Krumbholz, Steven Schmid, Yibin Xiang,
Michael Booker, James Lillie, Kara Carter
Genzyme Corporation, Waltham, Massachusetts, United States of America
Abstract
Increased metabolism is a requirement for tumor cell proliferation. To understand the dependence of tumor cells on fatty
acid metabolism, we evaluated various nodes of the fatty acid synthesis pathway. Using RNAi we have demonstrated that
depletion of fatty-acid synthesis pathway enzymes SCD1, FASN, or ACC1 in HCT116 colon cancer cells results in cytotoxicity
that is reversible by addition of exogenous fatty acids. This conditional phenotype is most pronounced when SCD1 is
depleted. We used this fatty-acid rescue strategy to characterize several small-molecule inhibitors of fatty acid synthesis,
including identification of TOFA as a potent SCD1 inhibitor, representing a previously undescribed activity for this
compound. Reference FASN and ACC inhibitors show cytotoxicity that is less pronounced than that of TOFA, and fatty-acid
rescue profiles consistent with their proposed enzyme targets. Two reference SCD1 inhibitors show low-nanomolar
cytotoxicity that is offset by at least two orders of magnitude by exogenous oleate. One of these inhibitors slows growth of
HCT116 xenograft tumors. Our data outline an effective strategy for interrogation of on-mechanism potency and pathway-
node-specificity of fatty acid synthesis inhibitors, establish an unambiguous link between fatty acid synthesis and cancer cell
survival, and point toward SCD1 as a key target in this pathway.
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Introduction
The fatty-acid content of cells in the body is derived from the
diet and from de novo synthesis. Rapidly-proliferating cancer cells
often have a robust program of fatty acid synthesis accompanied
by high-level expression of associated genes such as fatty-acid
synthase [1]. Because of its relative abundance in cancer cells,
fatty-acid synthase has been pursued as an oncology target [2].
However, it is unclear whether fatty-acid synthase represents the
rate-limiting component in the fatty-acid synthesis pathway.
Long-chain fatty acids are critical for the rapid membrane
synthesis requirement in vigorously-growing cells and play key
roles in various signaling schemes [3]. Additionally, a suitable
balance of chain-lengths and degree of saturation is critical for
maintenance of membrane fluidity and curvature [4]. It has been
reported that inhibition of various steps in the fatty-acid synthesis
pathway causes inhibition of cancer cell growth, either because of
deficiency in downstream fatty acids per se, or because of buildup of
toxic pathway intermediates such as malonyl-CoA, or both [5].
Using a combination of siRNA and small molecule inhibitors,
coupled with a ‘‘fatty acid complementation’’ strategy, we have
identified stearoyl-coA desaturase 1 as an enzyme in the fatty acid
synthesis pathway that is essential for cancer cell viability. The
‘‘complementation’’ strategy allowed characterization of both
SCD1 as well as the specificity of various fatty-acid synthesis
inhibitors, and clarifies the mechanism by which SCD1 inhibition
restricts cancer cell proliferation. Our data outline an unambig-
uous link between fatty acid synthesis and cancer cell survival.
Results
Cancer cells are sensitive to loss of SCD1 function
To examine the effect of interruption of fatty acid synthesis on
cancer cell viability, we used siRNA pools to deplete three nodes in
the pathway for synthesis of long-chain fatty acids (Figure 1A). As
shown in Figure 1B, depletion of acetyl-CoA carboxylase (ACC1),
fatty acid synthase (FASN), or stearoyl-CoA desaturase (SCD1)
results in decreased viability (or cellular metabolism) (as measured
by cellular ATP levels using Cell-Titer Glo) in HCT116 colon
cancer cells, by 30%, 30%, and 70%, respectively, versus a non-
targeting siRNA control, which was designated as 100% viability
In each case, mRNA knockdown was determined by real-time
RT-PCR to be approximately 80% (not shown). We reasoned that
if this cytotoxicity is truly gene-linked and on-target, and if
interruption of the fatty acid synthesis pathway results in reduced
cell viability owing to a deficiency in downstream fatty acids as
opposed to buildup of toxic pathway intermediates, then
cytotoxicity caused by depletion of various pathway nodes should
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downstream of that node. As shown in Figure 1B, ACC1 depletion
and FASN depletion are rescuable by palmitate, stearate, and
oleate, all of which are downstream of both ACC1 and FASN.
SCD1 depletion is not rescuable by palmitate or stearate (which are
upstream of SCD1), but SCD1 depletion is significantly rescued by
oleate(whichisdownstreamofSCD1).Reducedcellviabilitycaused
by depletion of two essential genes of unrelated mechanism,
PSMD14 and RNA polymerase II (Pol II) is not rescued by any of
the fatty acid treatments. This suggests that reduced cell viability
caused by treatment with these siRNAs is truly attributable to
depletion of the target gene, and that it is caused by a deficiency in
synthesis of fatty acids, as opposed to a buildup of toxic pathway
intermediates in the normal culture condition.
To examine the scope of SCD1 involvement in cancer cell
survival, several cancer cell lines were subjected to SCD1 or
PSMD14 RNAi treatment, in both cases using a single siRNA.
Viability of DU145 prostate cancer cells, HCT116 colon cancer
cells, and MIA PaCa2 pancreatic cancer cells is reduced (relative
to a non-targeting control siRNA) by depletion of both genes as
shown in Figure 1C. In all cases, SCD1-depletion-mediated
cytotoxicity is rescuable by supplementation of the media with
oleate, whereas in all cases PSMD14 depletion is not. This suggests
that a variety of cancer cells depend on synthesis of mono-unsaturated
fatty acids for cell viability, and that SCD1 is a critical node in the
pathway that may be a suitable therapeutic target.
The fatty acid synthesis pathway has been studied in the context
of both metabolic disease [6] and cancer [7]. Therefore a variety
of fatty-acid synthesis inhibitors are available. We set out to use the
fatty-acid rescue strategy with several such compounds, as a means
of both testing the hypothesis that fatty acid synthesis, and SCD1
activity in particular, are necessary for cancer cell viability, and
also with the goal of better understanding the on- and off-
mechanism activities of the fatty-acid synthesis inhibitors them-
selves. As shown in Figure 1D, reference inhibitors for ACC1
(Pfizer #CP640186 [8]), FASN (Merck #10v [9]), and SCD1
(Abbott #7n [10]) all display cytotoxicity and rescue profiles
consistent with the pathway position of the target. Toxicity due to
ACC1 and FASN inhibition is rescued by palmitate, stearate, and
oleate, whereas toxicity due to SCD1 inhibition is rescued only by
oleate. It is also noteworthy that the potency of these inhibitors
reflects the observation with siRNA. Despite the fact that the
reference inhibitors are of comparable potency in biochemical
assays on their respective targets, ACC1 and FASN inhibition
yield a modest viability reduction, whereas the phenotype with
SCD1 inhibition is more pronounced, suggesting the SCD1 is a
particularly valuable, perhaps rate-limiting node in this pathway.
These observations also suggest that the reference inhibitors are
free from dominant (non-rescuable) off-mechanism toxicity in this
cell system. The saturated long-chain fatty acids used in the rescue
scenario themselves produce a modest viability reduction at the
concentrations used. It is noteworthy that these saturated fatty
acids are synergistic with the SCD1 inhibitor (Figure 1D). This
suggests that while the bulk of the viability impact seen upon
SCD1 inhibition is due to depletion of mono-unsaturated fatty
acids, SCD1 inhibition also reduces the cells’ ability to mitigate the
effects of unnatural, exogenous saturated fatty acids, presumably
by ‘‘detoxification’’ to oleate or palmitoleate.
Inhibitor activity clarification by complementation
We tested three commercial widely-used historical inhibitors of
the fatty-acid synthesis pathway using the ‘‘fatty acid rescue’’
strategy. Cerulenin and C75 are FASN inhibitors [11,12], and
TOFA is an ACC1 inhibitor [13]. As shown in Figure 2A,
cerulenin and C75 both inhibit HCT116 colon cancer cell viability
as expected. However, neither of these inhibitors is responsive to
palmitate, stearate, or oleate, suggesting that both of these
inhibitors have dominant, non-mechanism-based cytotoxicity in
this cell system, and that reduction in cell viability driven by these
compounds is unrelated to inhibition of fatty acid synthesis.
In this assay, TOFA toxicity is rescued effectively by oleate, but
not by palmitate or stearate (Figure 2A), contrary to the
expectation for a specific inhibitor of ACC1. This pattern of
fatty-acid rescue is consistent with TOFA inhibition of SCD1.
Alternatively, TOFA-driven cytotoxicity could be altogether off-
target (unrescuable by palmitate or stearate), and TOFA could, in
principle, physically interact with oleate in the culture medium
such that oleate simply prevents TOFA from entering the cells. To
test this possibility, we added oleate at various times relative to the
time of TOFA addition, and measured viability in all cases at
72 hours after TOFA treatment. As shown in Figure 2B, oleate
addition up to 8 hours after TOFA addition yields a degree of
‘‘rescue’’ that is indistinguishable from the case where oleate is
added prior to TOFA addition. In this case, TOFA has hours to
permeate the cell and inhibit the target, prior to introduction of
oleate. This is inconsistent with oleate simply preventing TOFA
from entering the cells. When oleate is added 24 hours following
TOFA addition, the phenotype reversal is significantly compro-
mised. Therefore, between 8 and 24 hours after TOFA treatment,
the cells go past a ‘‘point of no return,’’ and become unresponsive
to oleate when assayed for viability at 72 hours.
Additionally we considered that oleate may be a promiscuous
‘‘cytotoxicity-rescue-agent.’’ To test this possibility, we tested a
variety of cytotoxic compounds in the oleate-rescue assay. As
shown in Figure 2C of a variety of inhibitors of various
mechanisms tested (including C75 and cerulenin), only TOFA-
driven cytotoxicity is rescuable by oleate. This is inconsistent with
oleate acting as a general ‘‘rescue-agent.’’
To test the hypothesis that the TOFA ‘‘fatty acid rescue profile’’
truly reflects TOFA inhibition of SCD1, we monitored conversion
of stable-isotope-labeled fatty acids by LC/MS/MS for fatty-acid
flux in the absence or presence of TOFA. We examined the
SCD1-mediated desaturation of 13C-palmitate or 13C-stearate to
palmitoleate or oleate, respectively, and the elongation of 13C-
palmitate to stearate following a 1-hour TOFA exposure.
Additionally, to gauge ACC1 inhibition, we monitored 13C-
acetate incorporation into palmitate. As shown in Figure 2D,
TOFA inhibits both SCD1-mediated desaturation events at a
potency comparable to its cell-viability EC50, and comparable to
its potency on ACC1. Conversely, substantially higher levels of
TOFA are required to effect the (non-SCD1-driven) elongation of
palmitate to stearate. Therefore, based on the fatty-acid rescue
profile and the direct measurement of SCD1 inhibition in living
cells, TOFA inhibits SCD1, which is a previously undescribed
activity for TOFA.
In the case of both TOFA and SCD1 inhibitor #7n (Figures 1D
and 2A), exogenous palmitate augments the impact of SCD1
inhibition. Beyond the fact that in this assay setting palmitate shows
some intrinsic cell viability inhibition, palmitate also left-shifts the
EC50 for TOFA and #7n, suggesting that the combination of
unnaturally elevated palmitate, and the inability to process it into
oleate, enhances viability inhibition of cancer cells.
Cancer cell viability inhibition tracks with inhibitor
potency and SCD1 represents the sole essential
desaturation route
To test the fidelity and correlation of our fatty-acid-rescue
viability studies and the cellular SCD1-inhibition LC/MS/MS
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33823Figure 1. SCD1 is a fatty acid synthesis pathway node critical for cancer cell survival. A de novo synthesis of mono-unsaturated fatty acids.
B HCT116 colon cancer cells (ATCC) cultured in RPMI-1640 (Cambrex) containing 2%FBS plated at a density of 4000 cells per well in 100 ul media in
96-well plates were transfected with siRNA pools (Dharmacon, 50 nM) targeting three fatty-acid-synthesis pathway nodes,or two unrelated survival
genes, using Lipofectamine 2000 (Invitrogen). 16 hours after transfection, cells were treated with 25 uM fatty acids (Sigma, 1006stocks dissolved in
10%MeOH/0.9%BSA/PBS) as indicated, and viability was determined 72 hours after transfection (Cell Titer Glo, Promega). Results are expressed as
percent viability versus cells transfected with a non-targeting control siRNA (designated 100% viability) treated with the same fatty acid. C DU145
prostate cancer cells, HCT116 colon cancer cells, and MIA PaCa2 pancreatic cancer cells (ATCC) cultured in RPMI-1640 containing 2% FBS were treated
with single siRNAs targeting SCD1 or PSMD14 (Dharmacon, 25 nM), followed 16 hours later by treatment with oleate as indicated. Viability was
determined 72 hours after transfection. Results are expressed as percent viability versus cells transfected with a non-targeting control siRNA
(designated 100% viability) treated with the same fatty acid. D HCT116 colon cancer cells plated at a density of 1000 cells per well in 25 ul media in
384-well plates were treated with small-molecule inhibitors of ACC1 (CP640186, Pfizer), FASN (#10v, Merck), or SCD1 (#7n, Abbott), in media
containing fatty acids as indicated, 72 hours prior to viability determination. Inibitors were synthesized at Genzyme (Waltham, MA).
doi:10.1371/journal.pone.0033823.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33823Figure 2. Characterization of various fatty acid synthesis reference inhibitors. A HCT116 colon cancer cells were treated with small-
molecule FASN inhibitors C75 and Cerulenin (Sigma), or the ACC inhibitor TOFA (Sigma), in media containing fatty acids as indicated, 72 hours prior
to viability determination. B HCT116 cells were treated with oleate at various times relative to the time of TOFA addition. Cell viability was
determined 72 hours after TOFA treatment. C HCT116 cells were treated with compounds in media lacking or containing oleate, followed by viability
determination after 72 hours. D HCT116 colon cancer cells cultured at a density of 1610
6 cells per 1 ml media per well in 12-well plates were pre-
treated with TOFA for one hour, followed by 13C-Palmitate or 13C-Stearate or 13C-Acetate (Sigma) treatment for four hours. Labeled fatty acids and
esters were extracted, saponified, and analyzed by LC/MS/MS using either an API 5000 or API 4000 triple quadrupole mass spectrometer (AB Sciex,
Forster City, CA) hyphenated with an Agilent 1100 HPLC system (Agilent, Santa Claire, CA). LC separation was accomplished using Xbridge phenyl
2.16100 mm column (Waters, Milford, MA). Mobile phase A consisted of 5 mM ammonium formate in deionized water. Mobile phase B consisted of
5 mM ammonium formate in methanol. The sample loading buffer consisted of 30% buffer A and 70% buffer B. A linear gradient was used for the
separation (70% to 100% B in 5 min). Samples were ionized by ESI in the negative ion mode and the dwell time for the MRM was 75 ms.
doi:10.1371/journal.pone.0033823.g002
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Abbott #7n, and Abbott #28c [14]. As shown in Figure 3A, #7n
is several-fold more potent than TOFA, and more oleate-
rescuable, in the cell-viability assay, and similarly is more potent
than TOFA in the direct cellular SCD1 inhibition assay. Similarly,
#28c is substantially more potent than #7n in the direct cellular
SCD1 inhibition assay, and also in the cell viability assay, while
completely retaining oleate-rescuability.
We considered that other unsaturation events may be available
to support cancer cell viability, via desaturases other than SCD1, if
cells are given sufficient supply of saturated substrate. To explore
this possibility, as well as to further characterize the specificity of
the #28c SCD1 inhibitor we examined a panel of fatty acids of
varying chain lengths and saturation states for their ability to
‘‘complement’’ (prevent the effect of) SCD1-inhibitor-mediated
viability reduction. As shown in Figure 3B, while not all
unsaturated fatty acids complemented, all ‘‘complementing’’ fatty
acids did contain at least one unsaturated bond. On the other
hand, all saturated fatty acids failed to complement, suggesting
that unsaturation is absolutely required for complementation, and
that alternative desaturase activities cannot be employed.
We examined TOFA, #7n, and #28c for induction of the
apoptosis cascade. HCT116 cells were treated with compound
doses equivalent to, or ten-fold above, their cytotoxocity IC50. As
shown in Figure 3C, all three fatty-acid synthesis inhibitors induce
PARP cleavage in a dose-dependent fashion, suggesting that
interruption of fatty-acid synthesis in these cells causes apoptosis.
The induction of PARP cleavage correlates with cell death in that
it is reversible with exogenous oleate (Figure 3D). PARP cleavage
is a marker of apoptosis [15].
SCD1 inhibition slows tumor growth and is not
universally toxic
The impact of SCD1 depletion on several cancer cell lines raises
the possibility that SCD1 inhibition will be universally toxic. We
tested the ovarian cancer cell line SKOV3 for sensitivity to a
reference SCD1 inhibitor. As shown in Figure 4A, the SCD1
inhibitor has limited impact on SKOV3 cell viability, versus
HCT116, despite having comparable inhibitory effect on cellular
conversion of stearate to oleate (SCD1 activity). We considered
that SKOV3 may be generally insensitive to various toxic agents.
As shown in Figure 4B, SKOV3 and HCT116 are comparably
sensitive to a variety of mechanistically-distinct toxic compounds,
such as dimethylsphingosine and daunorubicin, whereas in the
case of SCD1 inhibitors, SKOV3 is quite insensitive relative to
HCT116. This suggests that SKOV3 has some specific insensi-
tivity to fatty-acid-synthesis inhibition, and that SCD1 inhibition
will not be universally toxic.
SCD1 inhibitor #28c was recently described by Abbott [14] as
a potent, orally-available SCD1 inhibitor with favorable pharma-
cokinetic properties. Therefore this molecule provides a tool for in
vivo SCD1 target validation for cancer. We treated mice bearing
200 mm3 HCT116 tumors twice daily with #28c by oral gavage
(versus IV CPT11 on an optimized dosing regimen) for 20 days
and monitored tumor growth and body weight. As in Figure 4C,
#28c showed moderate growth delay of HCT116 tumors. While
the SCD1 inhibitor did reduce the oleate content of excised
tumors (not shown), substantial oleate remained in the tumor
tissue, raising the possibility that dietary oleate may be limiting for
efficacy of the SCD1 inhibitor. Treatment with the SCD1
inhibitor was accompanied by weight loss approaching 20%, or
reduction from 20 g to approximately 16 g, on dosing day 10
(study day 26) (Figure 4D) that was recovered after cessation of
dosing (study day 36). It is unclear whether this weight loss is
on-mechanism for this inhibitor (as might be expected from an
inhibitor of lipid synthesis), or unrelated to SCD1 inhibition.
Discussion
Cancer cells are distinct from nonmalignant cells based partly
on their unique metabolic status , one element of which is an
unusual requirement for fatty acid synthesis [16]. Thus the fatty
acid synthesis pathway has been an attractive cancer target for
some time, and primary attention has focused on fatty acid
synthase, which marks the point of production of long-chain fatty
acids [17]. Our experiments and others [18] suggest, however, that
the rate-determining step in synthesis of mono-unsaturated fatty
acids is at the point of de-saturation (by SCD1), and that SCD1
represents a particularly vulnerable node in this pathway. Using
both siRNA and reference inhibitors, we have shown that loss of
SCD1 activity yields pronounced viability inhibition of various
cancer cells in vitro. The fact that this viability inhibition is
reversible when oleate is added to the cell culture medium argues
that the phenotype is on-mechanism, and attributable to an
SCD1-inhibition-mediated oleate deficiency, as opposed to the
buildup of intracellular palmitate or other upstream pathway
components. We propose that this fatty-acid rescue strategy is a
simple, broadly useful mechanism for characterization of fatty acid
synthesis inhibitor specificity, as evidenced by our characterization
of the SCD1 inhibitory activity of TOFA.
HCT116 tumor growth is delayed upon treatment with a
potent, orally-available SCD1 reference inhibitor. However,
tumor growth delay is moderate, falling considerably short of that
seen with CPT11, which served as a positive control. It is
noteworthy, though, that an optimized dosing regimen was not
established for the SCD1 inhibitor. Tumor growth delay was
accompanied by weight loss, and decreased body weight was
sustained throughout the course of dosing. SCD1 was originally
investigated as a target for metabolic disorders, and it would not be
surprising if some portion of the observed weight loss was due to
broad inhibition of mono-unsaturated fatty acid synthesis. Addition-
ally, while SCD1 knockout mice are viable [19], mice have several
SCD isoforms, which may be redundant. If the toxicity (weight
loss) seen in the current study is due to fatty acid synthesis
inhibition, this may be attributable to the SCD1 inhibitor targeting
multiple murine SCD isoforms. This was not tested. Nevertheless,
in principle this would differentiate the inhibitor-driven toxicity
profile from the genetic SCD1 knockout. Alternatively, the weight
loss seen could be the net effect of SCD1-inhibition-driven
reduced adiposity and increased energy expenditure, comparable
to that seen in the SCD1 knockout [19,20].
Mono-unsaturated fatty acid maturation and processing,
following production by SCD1, is a complex network leading to
a host of different chain lengths, saturation states, and subcellular
distribution fates. It may be that while SCD1 represents a final,
rate-limiting ‘‘point-of-constriction’’ in the pathway, a downstream
enzyme target, along one of a variety of mono-unsaturated fatty-
acid processing sub-pathways, may represent a node that is
specifically required for cancer cell viability, and dispensable for
normal cell function. It may also be the case that SCD1 inhibition
could be productive in a co-treatment scenario, at low doses in
conjunction with a traditional agent.
Materials and Methods
Cell Culture
HCT116, DU145, and MIA PaCa2 cancer cells were
obtained from ATCC and maintained in RPMI1640 (Cambrex)
SCD1 Is a Cancer Cell Survival Gene
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For assays, cells were plated in RPMI1640 lacking penn-strep and
containing 2% FBS at a density of 4000 cells/100 ul/well in 96
well plates for siRNA treatment and viability determination, or at
a density of 1000 cells/25 ul/well in 384 well plates for compound
treatment and viability determination, or a density of 1610
6 cells/
1 ml/well in 12-well plates for compound treatment and LC/MS/
MS analysis of labeled fatty-acid flux. All cells were grown as a
monolayer in 95% air/5% CO2, and a single lot of non-
delipidated FBS was used for all experiments
Fatty Acid Preparation
Fatty acids (Sigma) were dissolved in methanol to a concentra-
tion of 25 mM. 25 mM stocks were then diluted ten-fold in PBS
(Cambrex) containing 0.9% BSA (A9576, Sigma). These 2.5 mM
(100X) stocks were thoroughly mixed and incubated in a 37 degree
Figure 3. SCD1 inhibitors are potent, specific, and kill cancer cells exclusively by depleting mono-unsaturated fatty acids. A HCT116
cells were treated and analyzed for cell viability or cellular SCD1 inhibition (LC/MS/MS) as described above. B HCT116 were treated with DMSO or
SCD1 inhibitor #28c in the presence of various fatty acids (25 uM) (Biomol, #2803) for 72 hours, and analyzed for cell viability. Data are displayed as
a heat map continuum from green (live cells) to red (dead cells). C HCT116 cells were treated for 36 hours with various doses of SCD1 inhibitors as
indicated. Cells were lysed in LDS loading dye (Invitrogen) and analyzed by western blotting for PARP cleavage (Cell Signaling). Staurosporine, a
broad-spectrum kinase inhibitor, was included as a positive control for PARP cleavage. D HCT116 cells were treated as in C, in the presence or
absence of exogenous oleate, followed by analysis of PARP cleavage.
doi:10.1371/journal.pone.0033823.g003
SCD1 Is a Cancer Cell Survival Gene
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33823water bath for one hour prior to aliquoting and freezing at 220
degrees. The fatty acid panel from Biomol (#2803) was dissolved
in DMSO.
LC/MS/MS Analysis
All experiments were performed by using a API 5000 or API
4000 triple quadrupole mass spectrometer (AB/MDS Sciex,
Concord, Canada) and an Agilent 1100 HPLC pump (Agilent,
Andover, MA). Columns were Xbridge phenyl 2.16100 mm
(Waters, Milford, MA). Buffer A was water with 5 mM
ammonium formate; buffer B was methanol 5 mM ammonium
formate; and loading buffer was 30% buffer A plus 70% buffer B).
A 5-min gradient (70% to 100%buffer B, linear) was used with
MRM acquisition time of 75 msec using negative mode. Fatty acid
synthesis determinations were expressed either as product/
(product+substrate) (in the case of stearate, palmitoleate, and
oleate synthesis), or as raw product normalized to unlabeled
linoleic acid (in the case of palmitate synthesis).
siRNA transfection
ON-Target-PLUS or siGENOME stock siRNAs (gene-specific
or non-targeting controls) were purchased from Dharmacon, and
transfected (50 nM (12.5 nM per each of four siRNAs) in the case
of siRNA pools (Smartpools), or 25 nM in the case of single
siRNAs using Lipofectamine 2000. The SCD1 single siRNA
sequence was: 59-GAACAGUGCUGCCCACCUC-39. The
PSMD14 single siRNA sequence was: 59-GGCAUUAAUU-
CAUGGACUA-39. Sixteen hours after transfection, 1/100
th
Figure 4. SCD1 inhibition is not universally toxic, and slows growth of HCT116 xenograft tumors. A HCT116 or SKOV3 cells were treated
and analyzed for cell viability or cellular SCD1 inhibition (LC/MS/MS) as described above. B HCT116 or SKOV3 cells were treated and analyzed for cell
viability. Table expresses the ratio of SKOV3 EC50 versus HCT116 EC50. C, D Nude mice harboring passage five 200 mm3 HCT116 tumors (passaged
as trocar fragments) (n=10 per group) were dosed by oral gavage twice daily with 160 mg/kg #28c for 20 days or with intravenous CPT11 on three
consecutive days starting when tumors reached 200 mm3. Tumor growth (C) and body weight (D) were monitored and plotted as mean +/2
standard deviation.
doi:10.1371/journal.pone.0033823.g004
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oleate) (100X=2.5 mM) or vehicle alone was added. Seventy-two
hours after transfection, 25 ul Cell-titer Glo was added and plates
were analyzed for cell viability according to the manufacturer
(Promega) recommendation. All analyses were performed in
duplicate or triplicate, on multiple occasions with similar
outcomes, and are graphed as the mean 6 SD of a single
representative experiment.
Small-molecule inhibitor treatment
C75, cerulenin, and TOFA were purchased from Sigma. ACC
inhibitor CP640186 (Pfizer), FASN inhibitor #10v (Merck), and
SCD1 inhibitors #7n and #28c (Abbott) were synthesized at
Genzyme (Waltham, MA). Compounds were dissolved in DMSO
and stored at 220 degrees. In the case of both BSA-complexed
fatty acid (or vehicle) and small-molecule inhibitors (or DMSO),
agents were pre-diluted in assay culture medium to 76 final
concentration. 5 ul apiece of 76stocks of two appropriate agents
was added to 25 ul medium, for 35 ul final volume. 72 to 96 hours
later, 7.3 ul Cell-titer Glo was added, and plates were analyzed for
cell viability. All analyses were performed in duplicate or triplicate,
on multiple occasions with similar outcomes, and are graphed as
the mean 6 SEM of a single representative experiment.
HCT116 Xenograft
Animal studies (#GENZ100507-20) were performed following
approval of Genzyme Institutional Animal Care and Use
Committee (IACUC). HCT116 tumors were passaged as trocar
fragments in nu/nu mice. Animals bearing passage five tumors
were treated with #28c (160 mg/kg twice daily oral dosing for 20
days) or CPT11 (once daily intravenous dosing for three
consecutive days) when tumors reached 200 mm3.
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